



PRESS RELEASE

2025-12-19

Miris AB Signs Distribution Agreement with Almazar Medical Corp to Expand Its Presence in the Middle East

Miris AB today announces the signing of a new distribution agreement with Almazar Medical Corp, a prominent provider of medical solutions in the Middle East. Through the partnership, Almazar Medical Corp gains the rights to distribute Miris products and solutions in Saudi Arabia, Bahrain, the United Arab Emirates, Kuwait, Qatar, Oman, Jordan, and Lebanon.

Miris AB announces the signing of a new distribution agreement with Almazar Medical Corp. The agreement strengthens Miris' commitment to improving neonatal nutrition globally and represents a significant expansion of the company's presence in one of the world's fastest-growing healthcare markets. The total medical technology market in the Middle East is valued at approximately 11 billion USD.

"The collaboration with Almazar Medical Corp marks an important milestone in our mission to make individualized fortification accessible worldwide," says Camilla Sandberg, CEO of Miris AB. "Their strong regional presence, technical expertise, and deep relationships within neonatal care in the region are major assets as Miris now enters one of the fastest-growing markets for medical technology."

"We are confident that this partnership will enable us to deliver greater value, expand our market reach, and meet our customers' growing needs with excellence and reliability. We look forward to a successful journey together," says Zaid Hasan, Executive Director, Almazar Medical Corp.

The agreement reflects Miris' continued commitment to expanding access to individualized fortification for preterm infants globally.

For more information contact:

Camilla Myhre Sandberg, CEO Miris Holding AB

Phone: +46 18 14 69 07

Email: camilla.sandberg@mirissolutions.com

Visit Miris webpage at: www.mirissolutions.com

About Miris

Miris is a global MedTech company developing and selling instruments and solutions for human milk analysis. The products are used at neonatal intensive care units, milk banks and research centers worldwide. The purpose is to enable clinicians to practice individualized nutrition of human milk using target fortification, thus giving preterm babies the best possible start in life. Miris received FDA clearance for the Human Milk Analyzer® for the US market in December 2018. The mission is to make individualized nutrition, based on breast milk, available globally to improve neonatal health. Miris Holding AB is listed on the Spotlight Stock Market in Sweden.